TRIUMEQ 50 MG — DIN 02430932
DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) : 50 MG ABACAVIR (ABACAVIR SULFATE) : 600 MG LAMIVUDINE : 300 MG · VIIV HEALTHCARE ULC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is TRIUMEQ?
TRIUMEQ 50 MG contains DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) : 50 MG ABACAVIR (ABACAVIR SULFATE) : 600 MG LAMIVUDINE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02430932, held by VIIV HEALTHCARE ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Oct-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRIUMEQ used for?
Treatment of Human Immunodeficiency Virus (HIV-1) infection in adults and adolescents aged 12 years and older and weighing at least 40 kg.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Lamivudine, Abacavir And Dolutegravir cost around the world?
Lamivudine, Abacavir And Dolutegravir is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Luxembourg | reimbursement | 8 | 8 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 3 | 3 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 3 | 3 | CZK███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
16 pack listings across 16 brand entries and 5 price bases, refreshed 05 Sep 2026. Ranges span every Lamivudine, Abacavir And Dolutegravir pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Supplied in 100 cc HDPE bottles containing 30 tablets and a silica gel desiccant. |
| Storage | Store in the original package (HDPE bottle with desiccant). (Note: Specific temperature range not provided in the snippet, though standard is often 15-30°C). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Lamivudine, Abacavir And Dolutegravir |
|---|---|
| ATC code | J05AR13 |
| AHFS class | 08:18.08.20 ; 08:18.08.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02430932 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2430932 |
| Brand name | TRIUMEQ |
| Generic / active ingredient | DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) : 50 MG ABACAVIR (ABACAVIR SULFATE) : 600 MG LAMIVUDINE : 300 MG |
| Market authorization holder | VIIV HEALTHCARE ULC |
| Health Canada schedule | Prescription |
| ATC code | J05AR13 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AR |
| Current status | MARKETED |
| Status date | 22-Oct-2014 |
| Original market date | 2014-10-22 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
One tablet once daily with or without food. Not for patients requiring dose adjustments (e.g., renal/hepatic impairment). Adjust dolutegravir dose to 50 mg BID if taken with certain enzyme inducers.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to any ingredient; HLA-B*5701 positive status; prior abacavir hypersensitivity; co-administration with dofetilide or fampridine (dalfampridine).
Warnings and precautions
Fatal hypersensitivity reactions (screen for HLA-B*5701); post-treatment HBV exacerbations; hepatotoxicity; lactic acidosis/severe hepatomegaly; pancreatitis; risk of myocardial infarction.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC J05AR
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tenofovir Disoproxil And Emtricitabine | AG-EMTRICITABINE / TENOFOVIR DISOPROXIL FUMARATE · APO-EMTRICITABINE-TENOFOVIR · AURO-EMTRICITABINE-TENOFOVIR · JAMP EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE · +6 more | 10 | 9 | Yes |
| Emtricitabine, Tenofovir Disoproxil And Efavirenz | APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR · ATRIPLA · AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR · JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE · +5 more | 9 | 5 | Yes |
| Lamivudine And Abacavir | APO-ABACAVIR-LAMIVUDINE · APO-ABACAVIR-LAMIVUDINE TABLETS · AURO-ABACAVIR/LAMIVUDINE · JAMP ABACAVIR / LAMIVUDINE · +5 more | 9 | 4 | Yes |
| Zidovudine And Lamivudine | APO-LAMIVUDINE-ZIDOVUDINE · AURO-LAMIVUDINE/ZIDOVUDINE · COMBIVIR · JAMP LAMIVUDINE / ZIDOVUDINE · +1 more | 5 | 3 | Yes |
| Lopinavir And Ritonavir | KALETRA | 4 | 3 | Yes |
| Emtricitabine, Tenofovir Alafenamide And Bictegravir | BIKTARVY | 2 | 2 | Yes |
| Emtricitabine And Tenofovir Alafenamide | DESCOVY | 2 | 2 | Yes |
| Emtricitabine, Tenofovir Alafenamide And Rilpivirine | ODEFSEY | 1 | 1 | Yes |
| Darunavir And Cobicistat | PREZCOBIX | 1 | 1 | Yes |
| Emtricitabine, Tenofovir Alafenamide, Elvitegravir And Cobicistat | GENVOYA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · +3 more | 143 | 55 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TRIUMEQ called?
The same molecule, Lamivudine, Abacavir And Dolutegravir, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Dolutegravir Eva | Latin | Saudi Arabia |
| DOVATO | Latin | Czechia |
| INSTGRA | Latin | Bahrain |
| TIVICAY | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.